Ainos

Management frames AI Nose as SmellTech‑as‑a‑Service with subscriptions, implying potential recurring revenue and value-based pricing if the platform demonstrably reduces scrap, downtime, or safety incidents in fabs.

The three‑year $2.1 million ASE order validates willingness to pay in a high‑value environment, and front‑end commercial orders could help expand use cases and referenceability. Still, the customer base is highly concentrated, deployments are early, and near-zero recognized revenue in H1 2026 suggests limited realized pricing power to date.

Biotech programs remain pre-commercial. Until the company shows gross margin expansion with scaled subscriptions and stickiness across multiple sites and customers, we score pricing power as latent but unproven.